| scholarly article | Q13442814 |
| P50 | author | Edward A Fisher | Q38549204 |
| P2093 | author name string | David E Cohen | |
| P2860 | cites work | Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia | Q24294711 |
| The PCSK9 decade | Q24615397 | ||
| The LDL receptor | Q24658039 | ||
| The degradation of apolipoprotein B100: multiple opportunities to regulate VLDL triglyceride production by different proteolytic pathways | Q26824858 | ||
| Structure of N-Terminal Domain of NPC1 Reveals Distinct Subdomains for Binding and Transfer of Cholesterol | Q27646366 | ||
| Apolipoprotein E: far more than a lipid transport protein | Q28204471 | ||
| Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein | Q28206260 | ||
| Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis | Q28209813 | ||
| A carboxyl-terminal PDZ-interacting domain of scavenger receptor B, type I is essential for cell surface expression in liver | Q28214792 | ||
| Identification of scavenger receptor SR-BI as a high density lipoprotein receptor | Q28273182 | ||
| Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia | Q28282776 | ||
| Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E | Q28292492 | ||
| Regulation of hepatic lipogenesis by the transcription factor XBP1 | Q28507784 | ||
| Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly | Q28624200 | ||
| SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver | Q29547646 | ||
| Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease | Q29614897 | ||
| A receptor-mediated pathway for cholesterol homeostasis | Q29616158 | ||
| Long-term follow-up of patients with NAFLD and elevated liver enzymes | Q29620024 | ||
| Lipoprotein lipase: structure, function, regulation, and role in disease | Q30874419 | ||
| PNPLA3/adiponutrin functions in lipid droplet formation | Q32872131 | ||
| Cell cholesterol efflux: integration of old and new observations provides new insights. | Q33605655 | ||
| Transcriptional control of hepatic lipid metabolism by SREBP and ChREBP. | Q33672543 | ||
| Nonalcoholic fatty liver disease and serum lipoproteins: the Multi-Ethnic Study of Atherosclerosis | Q33724815 | ||
| Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I | Q33736540 | ||
| The role of the microsomal triglygeride transfer protein in abetalipoproteinemia | Q33913539 | ||
| Receptors and lipid transfer proteins in HDL metabolism. | Q33949639 | ||
| The plasma lecithins:cholesterol acyltransferase reaction | Q34220638 | ||
| Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism | Q34251160 | ||
| New insights into the regulation of HDL metabolism and reverse cholesterol transport | Q34428702 | ||
| Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy | Q34477657 | ||
| Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study | Q34501554 | ||
| Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis | Q34537191 | ||
| Complexity in the secretory pathway: the assembly and secretion of apolipoprotein B-containing lipoproteins | Q34634838 | ||
| Lipoprotein lipase: from gene to obesity | Q34968373 | ||
| Lipoprotein lipase: genetics, lipid uptake, and regulation. | Q35009933 | ||
| Importance of different pathways of cellular cholesterol efflux | Q35077379 | ||
| Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance. | Q35186665 | ||
| Formation and Metabolism of Prebeta-Migrating, Lipid-Poor Apolipoprotein A-I | Q35573328 | ||
| Human fatty liver disease: old questions and new insights | Q35588477 | ||
| The Framingham risk score and heart disease in nonalcoholic fatty liver disease. | Q35946523 | ||
| Narrative review: hepatobiliary disease in type 2 diabetes mellitus | Q35990131 | ||
| Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease | Q35993416 | ||
| ACAT2 is a target for treatment of coronary heart disease associated with hypercholesterolemia | Q36098704 | ||
| Hepatic sortilin regulates both apolipoprotein B secretion and LDL catabolism | Q36129135 | ||
| An Endocrine Perspective of Nonalcoholic Fatty Liver Disease (NAFLD). | Q36328050 | ||
| Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis | Q36357941 | ||
| Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. | Q36406570 | ||
| Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? | Q36492920 | ||
| New molecular insights into CETP structure and function: a review | Q36520363 | ||
| Insulin suppression of apolipoprotein B in McArdle RH7777 cells involves increased sortilin 1 interaction and lysosomal targeting | Q36532383 | ||
| Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis | Q36557194 | ||
| Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance | Q36585363 | ||
| Lipoprotein metabolism in nonalcoholic fatty liver disease | Q36682138 | ||
| Biochemistry and pathophysiology of intravascular and intracellular lipolysis | Q36708030 | ||
| Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States | Q36756206 | ||
| Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease | Q36788344 | ||
| Dyslipidemia in patients with nonalcoholic fatty liver disease. | Q36845703 | ||
| HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis | Q37156017 | ||
| Intestinal lipid absorption | Q37216738 | ||
| The many intersecting pathways underlying apolipoprotein B secretion and degradation | Q37240302 | ||
| Plasma phospholipid transfer protein (PLTP): review of an emerging cardiometabolic risk factor | Q37469242 | ||
| Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production | Q37698834 | ||
| Apolipoprotein B100 biogenesis: a complex array of intracellular mechanisms regulating folding, stability, and lipoprotein assembly | Q37746984 | ||
| Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease | Q37794163 | ||
| Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease | Q37850396 | ||
| The role of lecithin:cholesterol acyltransferase in the modulation of cardiometabolic risks - a clinical update and emerging insights from animal models | Q37983334 | ||
| Apolipoprotein C-III and hepatic triglyceride-rich lipoprotein production | Q38003289 | ||
| Rationale for cholesteryl ester transfer protein inhibition | Q38003957 | ||
| High-density lipoprotein function, dysfunction, and reverse cholesterol transport | Q38059859 | ||
| The regulation of ApoB metabolism by insulin | Q38110665 | ||
| The lipid droplet as a potential therapeutic target in NAFLD. | Q38162131 | ||
| The unfolded protein response in fatty liver disease | Q38162132 | ||
| Fatty infiltration of liver in hyperlipidemic patients | Q39554435 | ||
| Enhanced cellular uptake of remnant high-density lipoprotein particles: a mechanism for high-density lipoprotein lowering in insulin resistance and hypertriglyceridemia. | Q39971982 | ||
| The fate of HDL particles in vivo after SR-BI-mediated selective lipid uptake | Q40694088 | ||
| Hepatic uptake of chylomicron remnants | Q40876629 | ||
| Lipoprotein heterogeneity and apolipoprotein B metabolism | Q41686075 | ||
| Switch-like control of SREBP-2 transport triggered by small changes in ER cholesterol: a delicate balance | Q42254249 | ||
| The lipidation by hepatocytes of human apolipoprotein A-I occurs by both ABCA1-dependent and -independent pathways | Q42436201 | ||
| Fatty liver in familial hypobetalipoproteinemia: roles of the APOB defects, intra-abdominal adipose tissue, and insulin sensitivity | Q44766939 | ||
| A lipidomic analysis of nonalcoholic fatty liver disease. | Q44931121 | ||
| Non-alcoholic steatohepatitis in type 2 diabetes mellitus | Q44969998 | ||
| Hepatic lipase mRNA, protein, and plasma enzyme activity is increased in the insulin-resistant, fructose-fed Syrian golden hamster and is partially normalized by the insulin sensitizer rosiglitazone | Q45124397 | ||
| Hepatic lipase activity is increased in non-alcoholic fatty liver disease beyond insulin resistance. | Q47844166 | ||
| Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events. | Q51338670 | ||
| Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensit | Q53889392 | ||
| Insulin down-regulates specific activity of ATP-binding cassette transporter A1 for high density lipoprotein biogenesis through its specific phosphorylation. | Q54604551 | ||
| Hepatic steatosis and VLDL hypersecretion | Q60641816 | ||
| Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro | Q63408528 | ||
| Does non-alcoholic fatty liver impair alterations of plasma lipoproteins and associated factors in metabolic syndrome? | Q82894142 | ||
| Diagnostic accuracy of adipose insulin resistance index and visceral adiposity index for progressive liver histology and cardiovascular risk in nonalcoholic fatty liver disease | Q83525573 | ||
| P433 | issue | 4 | |
| P921 | main subject | lipoprotein | Q28350 |
| metabolic dysfunction–associated steatotic liver disease | Q1546498 | ||
| fatty liver disease | Q6058862 | ||
| dyslipidemia | Q66291209 | ||
| P304 | page(s) | 380-388 | |
| P577 | publication date | 2013-11-12 | |
| P1433 | published in | Seminars in Liver Disease | Q15724477 |
| P1476 | title | Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease | |
| P478 | volume | 33 |
| Q40887732 | A Pressure-dependent Model for the Regulation of Lipoprotein Lipase by Apolipoprotein C-II. |
| Q41705191 | Analysis of Hepatitis C Virus Particle Heterogeneity in Immunodeficient Human Liver Chimeric fah-/- Mice |
| Q58101515 | Anti-Hyperlipidemic Effects of Synthetic Analogs of Nordihydroguaiaretic acid (NDGA) in Dyslipidemic Rats |
| Q40350510 | Aromatic residues in the C terminus of apolipoprotein C-III mediate lipid binding and LPL inhibition |
| Q47221266 | Association of Antituberculosis Treatment and Lower Risk of Hyperlipidemia in Taiwanese Patients: A Population-Based Case-Control Study |
| Q47127406 | Associations between fatty liver index and asymptomatic intracranial vertebrobasilar stenosis in Chinese population |
| Q39174515 | Automation of PRM-dependent D3-Leu tracer enrichment in HDL to study the metabolism of apoA-I, LCAT and other apolipoproteins |
| Q33759921 | Dicer1/miR-29/HMGCR axis contributes to hepatic free cholesterol accumulation in mouse non-alcoholic steatohepatitis |
| Q28595874 | Dyslipidemia in rural areas of North China: prevalence, characteristics, and predictive value |
| Q41573763 | Endoplasmic Reticulum Stress Inducer Tunicamycin Alters Hepatic Energy Homeostasis in Mice |
| Q93010345 | Flaxseed oil in the context of a weight loss program ameliorates fatty liver grade in patients with non-alcoholic fatty liver disease: a randomized double-blind controlled trial |
| Q34775930 | Formation of fenestrae in murine liver sinusoids depends on plasmalemma vesicle-associated protein and is required for lipoprotein passage. |
| Q41986990 | Fructose metabolism, cardiometabolic risk, and the epidemic of coronary artery disease |
| Q38582214 | Functional foods as potential therapeutic options for metabolic syndrome. |
| Q64101637 | HCV Pit Stop at the Lipid Droplet: Refuel Lipids and Put on a Lipoprotein Coat before Exit |
| Q90020514 | HDL flux is higher in patients with nonalcoholic fatty liver disease |
| Q92540544 | HIIT is not superior to MICT in altering blood lipids: a systematic review and meta-analysis |
| Q35039330 | Hematopoietic Akt2 deficiency attenuates the progression of atherosclerosis |
| Q90047443 | Hepatocyte Injury and Hepatic Stem Cell Niche in the Progression of Non-Alcoholic Steatohepatitis |
| Q48363625 | Hepatoprotective effect of parthenolide in rat model of nonalcoholic fatty liver disease |
| Q36905761 | Increased levels of low-density lipoprotein cholesterol within the normal range as a risk factor for nonalcoholic fatty liver disease |
| Q90661971 | Insulin activates intracellular transport of lipid droplets to release triglycerides from the liver |
| Q35850407 | Lipoprotein Profiles in Class III Obese Caucasian and African American Women with Nonalcoholic Fatty Liver Disease. |
| Q34718630 | Liver histology during Mipomersen therapy for severe hypercholesterolemia |
| Q101461111 | Loss of Hepatic Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 Links Nonalcoholic Steatohepatitis to Atherosclerosis |
| Q36121702 | Metabolic and Body Composition Risk Factors Associated with Metabolic Syndrome in a Cohort of Women with a High Prevalence of Cardiometabolic Disease |
| Q28067490 | Metabolic aspects of adult patients with nonalcoholic fatty liver disease |
| Q36731728 | Multiple apolipoprotein kinetics measured in human HDL by high-resolution/accurate mass parallel reaction monitoring |
| Q47131162 | Non-HDL cholesterol and LDL cholesterol in the dyslipidemic classification in patients with nonalcoholic fatty liver disease |
| Q58731134 | Non-HDL-cholesterol to HDL-cholesterol ratio is a better predictor of new-onset non-alcoholic fatty liver disease than non-HDL-cholesterol: a cohort study |
| Q38555120 | Non-alcoholic fatty liver disease as a consequence of autonomic imbalance and circadian desynchronization |
| Q38730392 | Normal weight dyslipidemia: Is it all about the liver? |
| Q39945625 | Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients |
| Q100444139 | Per- and Polyfluoroalkyl Substance Toxicity and Human Health Review: Current State of Knowledge and Strategies for Informing Future Research |
| Q51068461 | Phosphatidylcholine transfer protein/StarD2 promotes microvesicular steatosis and liver injury in murine experimental steatohepatitis. |
| Q35662655 | Physiology and pathophysiology of liver lipid metabolism. |
| Q39259913 | Review: Metabolic Syndrome in Black South African Women |
| Q37392542 | Risk factor compositions of nonalcoholic fatty liver disease change with body mass index in males and females |
| Q36818384 | Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease |
| Q90273777 | Thioesterase Superfamily Member 2 Promotes Hepatic VLDL Secretion by Channeling Fatty Acids Into Triglyceride Biosynthesis |
| Q47719467 | Triglyceride Metabolism in the Liver. |
| Q58550770 | Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy |
| Q26746279 | Triglyceride-Rich Lipoproteins and Remnants: Targets for Therapy? |
| Q57069563 | rs139051 is associated with phospholipid metabolite profile and hepatic inflammation in nonalcoholic fatty liver disease |
Search more.